Incyte

Incyte Down as FDA Extends Review Period of Jakafi for GVHD
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
Yahoo/Zacks.com
Incyte
FDA
Jakafi
graft vs host disease
Flag link:
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
BioSpace
Eli Lilly
Incyte
olumiant
atopic dermatitis
clinical trials
Flag link:
Mark Your Calendar For These February PDUFA Dates
Mark Your Calendar For These February PDUFA Dates
Yahoo/Benzinga
FDA
DWP-450
Evolus
MOTIF BIO PLC/S ADR
Iclaprim
Bausch Health
Duobrii
Merck
Keytruda
Incyte
Novartis
ruxolitinib
Novo Nordisk
N8-GP
Flag link:
Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
Investors Business Daily
Incyte
M&A
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Innovent, Incyte sign collaboration deal for three clinical-stage product candidates
Innovent, Incyte sign collaboration deal for three clinical-stage product candidates
Pharmaceutical Business Review
Incyte
Innovent Biologics
pemigatinib
itacitinib
parsaclisib
Flag link:
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
FDA
Incyte
Novartis
Jakavi
Jakafi
graft vs host disease
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
Incyte
graft vs host disease
Novartis
Jakafi
Flag link:
Agenus sells cut of Incyte, Merck milestone streams
Agenus sells cut of Incyte, Merck milestone streams
Fierce Biotech
Agenus
Incyte
Merck
Xoma
Flag link:
Incyte preps Jakafi expansion into graft-versus-host disease
Incyte preps Jakafi expansion into graft-versus-host disease
Biopharma Dive
Incyte
Jakafi
graft vs host disease
Flag link:
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Xconomy
Eli Lilly
Incyte
FDA
rheumatoid arthritis
olumiant
baricitinib
Flag link:
3 Biotechs With Huge FDA Decisions in June
3 Biotechs With Huge FDA Decisions in June
Motley Fool
biotech
Array Biopharma
encorafenib
binimetinib
GW Pharma
Epidiolex
Incyte
olumiant
Flag link:
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
Xconomy
ASCO
oncology
IDO inhibitors
Incyte
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination
Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination
Fierce Biotech
Incyte
epacadostat
Keytruda
IDO inhibitors
Flag link:
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
Xconomy
Eli Lilly
FDA
advisory panels
rheumatoid arthritis
baricitinib
Incyte
Flag link:
Big Week Ahead for Eli Lilly: Here's What to Look For
Big Week Ahead for Eli Lilly: Here's What to Look For
Motley Fool
Eli Lilly
earnings
FDA
Incyte
olumiant
rheumatoid arthritis
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Incyte
TG Therapeutics
Cara Therapeutics
CR845
opioids
ublituximab
leukemia
olumiant
rheumatoid arthritis
Flag link:
[video]Why One Drug Flop Tanked Incyte's Stock
[video]Why One Drug Flop Tanked Incyte's Stock
Motley Fool
Incyte
epacadostat
Flag link:

Pages